EUCTR2004-005157-63-IT进行中（未招募）不适用
An open label multicenter study to assess the pharmacokinetic, tolerability and safety of a pediatric formulation of bosentan in children with idiopathic or familial pulmonary arterial hypertension iPAH
ACTELION PHARMACEUTICALS ITALIA0 个研究点目标入组 35 人开始时间: 2006年2月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Pediatric Arthritis Study of Certolizumab pegolJuvenile Idiopathic ArthritisEUCTR2009-018027-33-Outside-EU/EEACB BIOSCIENCES GmbH
进行中（未招募）
3 期
Pediatric Arthritis Study of CertolizumabPegol (PASCAL)Juvenile Idiopathic Arthritis (JIA)RBR-6s67w4CB BIOSCIENCES GmbH
进行中（未招募）
1 期
A 4 week study with BI 144807 in patients >= 50 years with wet age related macular degeneratioewly diagnosed unilateral wet age-related macular degeneration (wAMD)MedDRA version: 17.0Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 100000004853EUCTR2013-004567-30-DEBoehringer Ingelheim Pharma GmbH & Co. KG30
进行中（未招募）
不适用
A 4 week study with BI 144807 in patients >= 50 years with wet age related macular degeneratioEUCTR2013-004567-30-ATBoehringer Ingelheim RCV GmbH & Co KG70
进行中（未招募）
不适用
A 4 week study with BI 144807 in patients >= 50 years with wet age related macular degeneratiopatients with newly diagnosed, unilateral, wet Are-Related Macular DegenerationMedDRA version: 17.0Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 100000004853EUCTR2013-004567-30-HUBoehringer Ingelheim RCV GmbH & Co KG70